Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3690 participants.

Also called NCT07625774

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,690 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07625774
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07625774. Randomized; quadruple masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2031-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease
Acronym
RENEW-CKD
Intervention (Drug)
HRS-7535
Intervention (Drug)
Placebo
Lead sponsor
Shandong Suncadia Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07625774
Content hash
a0bc837ad800cfebff128982094d748c28d38a0543c97342ade31202d4f08f69